Molidustat vs Roxadustat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline
Molidustat
Marketed by Bayer
NCT03543657 · Phase 3 · completed
The trial randomized 229 participants to molidustat or darbepoetin alfa with matching placebos and quadruple blinding. Its primary endpoints were hemoglobin measures, which are laboratory surrogate outcomes. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
The mean Hb level during the evaluation period (From week 33 to 36); The change in mean Hb level during the evaluation period from baseline (Baseline and week 33 to 36): Mean Hb during evaluation period (weeks 33-36): molidustat 10.63 g/dL (95% CI 10.42-10.84) vs darbepoetin alfa 10.77 g/dL (95% CI 10.59-10.95); LS mean difference -0.13 g/dL (95% CI -0.46 to 0.19); noninferiority (margin 1.0 g/dL) established (met)
Result source: NCT03543657
Roxadustat · Evrenzo
Marketed by Kyntra Bio and partners
NCT01750190 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled Phase 3 trial in 922 non-dialysis CKD patients with anemia. The two primary efficacy endpoints—mean change in hemoglobin over weeks 28-52 and hemoglobin response during the first 24 weeks—were both statistically significant and strongly favored roxadustat over placebo (p<0.0001 for both). The study was adequately powered and used a hard hemoglobin-based clinical endpoint, supporting a strong design and result.
Next expected readout: October 2027 · NCT05970172 (registry estimate)
Reported efficacy
United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy (Baseline (Day 1, Week 0), Weeks 28 to 52); Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy (Baseline up to Week 24): Mean hemoglobin change over Weeks 28-52: 2.00 g/dL roxadustat vs 0.16 g/dL placebo; least-squares mean difference 1.85 g/dL (95% CI 1.735-1.967; p<0.0001). Hemoglobin response during the first 24 weeks: 523/608 roxadustat vs 20/305 placebo; odds ratio 77.56 (95% CI 44.73-134.48; p<0.0001). (met)
Result source: NCT01750190
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Molidustat | Roxadustat |
|---|---|---|
| Kidney composite outcome | —Not posted · NCT03350347 | —Trial running · NCT05970172 |
| UACR, % change | —Not posted · NCT03350347 | —Trial running · NCT05970172 |
| eGFR slope | —Not posted · NCT03350347 | -2.6 vs -3.2+0.6 vs placeboNCT01887600 |
| Haemoglobin, change | —Not posted · NCT03350347 | 2 vs 0.2+1.8 vs placeboNCT01750190169 other results
|
Kidney composite outcome
- Molidustat
- —Not posted · NCT03350347
- Roxadustat
- —Trial running · NCT05970172
UACR, % change
- Molidustat
- —Not posted · NCT03350347
- Roxadustat
- —Trial running · NCT05970172
eGFR slope
- Molidustat
- —Not posted · NCT03350347
- Roxadustat
- -2.6 vs -3.2+0.6 vs placeboNCT01887600
Haemoglobin, change
- Molidustat
- —Not posted · NCT03350347
- Roxadustat
- 2 vs 0.2+1.8 vs placeboNCT01750190
169 other results
- 1.8 vs 0.4 NCT02174627
- 2.0 vs 0.3 NCT01887600
- 2.6 vs 2.4 NCT02052310
- 0.4 vs -0.1 NCT02273726
- 0.4 vs 0.2 NCT02278341
- 0.4 vs 0.2 NCT02278341
- 0.8 vs 0.7 NCT02174731
- 0.5 vs -0.0 NCT02273726
- 1.9 vs 0.5 NCT01887600
- 1.8 vs 0.3 NCT01887600
- 1.7 vs 0.1 NCT01887600
- 1.8 vs 0.4 NCT01887600
- 1.6 vs 0.4 NCT01887600
- 1.9 vs 0.5 NCT01887600
- 1.8 vs 0.3 NCT01887600
- 1.9 vs 0.7 NCT01887600
- 1.8 vs 0.3 NCT01887600
- 1.9 vs 0.4 NCT01887600
- 1.6 vs 0.2 NCT01887600
- 2.0 vs 0.4 NCT01887600
- 1.7 vs 0.1 NCT01887600
- 1.9 vs 0.3 NCT01887600
- 1.8 vs 0.6 NCT02174627
- 2.0 vs 0.3 NCT01887600
- 1.9 vs 0.2 NCT01887600
- 2.0 vs 0.2 NCT01750190
- 2.0 vs 0.2 NCT01750190
- 1.7 vs 0.2 NCT01887600
- 2.1 vs 0.4 NCT01887600
- 1.9 vs 0.3 NCT01887600
- 2.0 vs 0.4 NCT01887600
- 1.8 vs 0.4 NCT01887600
- 1.9 vs 0.2 NCT01887600
- 2.2 vs 0.4 NCT01887600
- 2.1 vs 0.2 NCT01887600
- 2.4 vs 0.4 NCT01887600
- 2.2 vs 0.2 NCT01887600
- 2.4 vs 0.3 NCT01887600
- 2.1 vs 0.2 NCT01887600
- 2.2 vs 0.2 NCT01887600
- 1.9 vs 0.1 NCT01887600
- 1.6 vs 0.1 NCT01887600
- 1.0 vs 0.0 NCT01887600
- 0.4 vs -0.0 NCT01887600
- 2.1 vs 0.5 NCT01887600
- 2.0 vs 0.4 NCT01887600
- 1.9 vs 0.3 NCT01887600
- 1.8 vs 0.3 NCT01887600
- 0.2 vs 0.1 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.1 vs -0.1 NCT02278341
- 0.4 vs 0.2 NCT02278341
- 0.0 vs -0.0 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.1 vs -0.0 NCT02278341
- 0.4 vs 0.2 NCT02278341
- 0.1 vs -0.0 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.2 vs -0.1 NCT02278341
- 0.4 vs 0.2 NCT02278341
- 0.2 vs 0.1 NCT02278341
- 2.6 vs 2.4 NCT02052310
- 0.4 vs 0.2 NCT02278341
- 0.2 vs 0.1 NCT02278341
- 0.3 vs 0.3 NCT02278341
- 0.2 vs 0.1 NCT02278341
- 0.5 vs 0.2 NCT02278341
- 0.4 vs 0.1 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.5 vs 0.3 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.3 vs 0.1 NCT02278341
- 0.5 vs 0.2 NCT02278341
- 0.4 vs 0.0 NCT02278341
- 0.6 vs 0.2 NCT02278341
- 0.5 vs 0.0 NCT02278341
- 0.7 vs 0.1 NCT02278341
- 0.6 vs -0.0 NCT02278341
- 0.8 vs 0.1 NCT02278341
- 0.7 vs -0.0 NCT02278341
- 0.9 vs 0.1 NCT02278341
- 0.7 vs -0.0 NCT02278341
- 0.8 vs 0.1 NCT02278341
- 0.6 vs 0.1 NCT02278341
- 0.9 vs 0.7 NCT02174731
- 2.3 vs 2.5 NCT02052310
- 0.6 vs -0.0 NCT02273726
- 0.5 vs 0.1 NCT02278341
- 0.2 vs 0.1 NCT02278341
- 0.8 vs 0.6 NCT02174731
- 2.7 vs 2.5 NCT02052310
- 1.2 vs 0.0 NCT00761657
- 1.5 vs 0.0 NCT00761657
- 0.8 vs 0.0 NCT00761657
- 1.3 vs 0.0 NCT00761657
- 0.5 vs 0.0 NCT00761657
- 0.1 vs 0.0 NCT00761657
- 0.6 vs 0.0 NCT00761657
- 0.2 vs 0.0 NCT00761657
- 0.7 vs -2.5 NCT01147666
- -2.0 vs -2.4 NCT01147666
- -0.4 vs -2.5 NCT01147666
- -0.6 vs -2.5 NCT01147666
- -0.1 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- -0.1 vs -2.4 NCT01147666
- -0.1 vs -2.4 NCT01147666
- 0.5 vs -2.4 NCT01147666
- -0.0 vs -2.4 NCT01147666
- 0.3 vs -2.4 NCT01147666
- 0.0 vs -2.4 NCT01147666
- 0.6 vs -2.4 NCT01147666
- 0.2 vs -2.4 NCT01147666
- 0.5 vs -2.4 NCT01147666
- 0.1 vs -2.4 NCT01147666
- 0.3 vs -2.5 NCT01147666
- -0.1 vs -2.5 NCT01147666
- 0.9 vs -2.5 NCT01147666
- -0.6 vs -2.5 NCT01147666
- -0.3 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- -0.1 vs -2.4 NCT01147666
- -0.2 vs -2.4 NCT01147666
- 0.0 vs -2.4 NCT01147666
- -0.2 vs -2.5 NCT01147666
- -0.4 vs -2.5 NCT01147666
- -0.8 vs -2.5 NCT01147666
- -0.3 vs -2.5 NCT01147666
- -0.6 vs -2.5 NCT01147666
- -0.8 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- -0.1 vs -2.4 NCT01147666
- -0.5 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- 0.0 vs -2.4 NCT01147666
- -0.4 vs -2.4 NCT01147666
- -0.2 vs -2.4 NCT01147666
- 0.3 vs -2.4 NCT01147666
- -0.6 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- 0.4 vs -2.4 NCT01147666
- -0.6 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- 0.3 vs -2.4 NCT01147666
- -0.5 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- 0.2 vs -2.4 NCT01147666
- -0.3 vs -2.5 NCT01147666
- -0.5 vs -2.5 NCT01147666
- 0.2 vs -2.5 NCT01147666
- 0.1 vs -2.5 NCT01147666
- -2.8 vs -2.5 NCT01147666
- 0.1 vs -2.4 NCT01147666
- -3.0 vs -2.4 NCT01147666
- -0.3 vs -2.4 NCT01147666
- -2.7 vs -2.4 NCT01147666
- -0.1 vs -2.4 NCT01147666
- -2.3 vs -2.4 NCT01147666
- -0.1 vs -2.4 NCT01147666
- -0.1 vs -2.4 NCT01147666
- -1.5 vs -2.4 NCT01147666
- 0.1 vs -2.4 NCT01147666
- -0.9 vs -2.4 NCT01147666
- 0 vs -2.5 NCT01147666
- -0.9 vs -2.5 NCT01147666
- -2.6 vs -2.5 NCT01147666
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Molidustat: 1 of 5 rows · Roxadustat: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Molidustat | Roxadustat |
|---|---|---|
| Hgb Target Range responder rate · % of participants No placebo or comparator arm | 54.9%a,b,c NCT03418168 · Phase 3 · sponsor-reported, not registry data | 65.7% (n=42) @ 24wka,b,c NCT03402386 · Phase 3 · registry result, not featured evidence 1 other source trial73.7% (n=24) @ 24wk NCT03461146 · Phase 3 · registry result, not featured evidence |
| Dropout rate | — | 43.3%d NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 40 more results22.6% NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 37.3% NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 7.7% NCT04655027 · Phase 4 · registry result, not featured evidence 18.2% NCT04410198 · Phase 3 · registry result, not featured evidence 26.5% NCT03329196 · Phase 3 · registry result, not featured evidence 25.9% NCT03439137 · Phase 3 · registry result, not featured evidence 14.3% NCT03402386 · Phase 3 · registry result, not featured evidence 12.5% NCT03461146 · Phase 3 · registry result, not featured evidence 6.1% NCT02174627 · Phase 3 · registry result, not featured evidence 6.6% NCT02174731 · Phase 3 · registry result, not featured evidence 41.2% NCT02052310 · Phase 3 · registry result, not featured evidence 65.7% NCT02273726 · Phase 3 · registry result, not featured evidence 28.4% NCT02278341 · Phase 3 · registry result, not featured evidence 66.7% NCT01630889 · Phase 2 · registry result, not featured evidence 8.3%2.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg NCT01147666 · Phase 2 · registry result, not featured evidence 80%2.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 16.7%1.8 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 41.7%1.8 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 16.7%1.5 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 50%1.5 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 25%1.3 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 16.7%1.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 20%Weight Tiered 70-120-200 mg NCT01147666 · Phase 2 · registry result, not featured evidence 25%Weight Tiered 70-100-150 mg NCT01147666 · Phase 2 · registry result, not featured evidence 25%Weight Tiered 70-120-200 mg NCT01147666 · Phase 2 · registry result, not featured evidence 4.2%100 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence 16%70 mg BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence 8.3%50 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence 12.5%Tiered, Weight Based Dosing TIW NCT01244763 · Phase 2 · registry result, not featured evidence 12.5%Tiered, Weight Based Dosing TIW Then BIW NCT01244763 · Phase 2 · registry result, not featured evidence 12.5%Tiered, Weight Based Dosing BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence 100%2.0 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 50%2.0 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence —1.5 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence —1.5 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence 33.3%1.0 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 60%1.0 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence —0.7 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence —0.7 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — | 7.6%d NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 40 more results0.6% NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 5.4% NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 — NCT04655027 · Phase 4 · registry result, not featured evidence 2% NCT04410198 · Phase 3 · registry result, not featured evidence 6.6% NCT03329196 · Phase 3 · registry result, not featured evidence 9.9% NCT03439137 · Phase 3 · registry result, not featured evidence 7.1% NCT03402386 · Phase 3 · registry result, not featured evidence 8.3% NCT03461146 · Phase 3 · registry result, not featured evidence — NCT02174627 · Phase 3 · registry result, not featured evidence — NCT02174731 · Phase 3 · registry result, not featured evidence 5.6% NCT02052310 · Phase 3 · registry result, not featured evidence 7.3% NCT02273726 · Phase 3 · registry result, not featured evidence 0.7% NCT02278341 · Phase 3 · registry result, not featured evidence — NCT01630889 · Phase 2 · registry result, not featured evidence 8.3%2.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg NCT01147666 · Phase 2 · registry result, not featured evidence 20%2.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%1.8 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%1.8 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 8.3%1.5 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%1.5 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%1.3 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 8.3%1.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%Weight Tiered 70-120-200 mg NCT01147666 · Phase 2 · registry result, not featured evidence 0%Weight Tiered 70-100-150 mg NCT01147666 · Phase 2 · registry result, not featured evidence 0%Weight Tiered 70-120-200 mg NCT01147666 · Phase 2 · registry result, not featured evidence 0%100 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence 4%70 mg BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence 0%50 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence 4.2%Tiered, Weight Based Dosing TIW NCT01244763 · Phase 2 · registry result, not featured evidence 0%Tiered, Weight Based Dosing TIW Then BIW NCT01244763 · Phase 2 · registry result, not featured evidence 0%Tiered, Weight Based Dosing BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence —1.5 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence —1.5 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%1.0 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 10%1.0 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence —0.7 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence —0.7 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence |
| Serious AEs | — | 52.5%d NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 40 more results64.7% NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 61.6% NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 0% NCT04655027 · Phase 4 · registry result, not featured evidence 25.6% NCT04410198 · Phase 3 · registry result, not featured evidence 27.8% NCT03329196 · Phase 3 · registry result, not featured evidence 25.3% NCT03439137 · Phase 3 · registry result, not featured evidence 28.6% NCT03402386 · Phase 3 · registry result, not featured evidence 29.2% NCT03461146 · Phase 3 · registry result, not featured evidence 57.4% NCT02174627 · Phase 3 · registry result, not featured evidence 57.6% NCT02174731 · Phase 3 · registry result, not featured evidence 44.8% NCT02052310 · Phase 3 · registry result, not featured evidence 65.4% NCT02273726 · Phase 3 · registry result, not featured evidence 50.7% NCT02278341 · Phase 3 · registry result, not featured evidence 60% NCT01630889 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg NCT01147666 · Phase 2 · registry result, not featured evidence 40%2.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 33.3%1.8 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 41.7%1.8 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 25%1.5 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 50%1.5 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 25%1.3 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 0%1.0 mg/kg TIW NCT01147666 · Phase 2 · registry result, not featured evidence 30%Weight Tiered 70-120-200 mg NCT01147666 · Phase 2 · registry result, not featured evidence 41.7%Weight Tiered 70-100-150 mg NCT01147666 · Phase 2 · registry result, not featured evidence 25%Weight Tiered 70-120-200 mg NCT01147666 · Phase 2 · registry result, not featured evidence 16.7%100 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence 40%70 mg BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence 16.7%50 mg TIW NCT01244763 · Phase 2 · registry result, not featured evidence 12.5%Tiered, Weight Based Dosing TIW NCT01244763 · Phase 2 · registry result, not featured evidence 16.7%Tiered, Weight Based Dosing TIW Then BIW NCT01244763 · Phase 2 · registry result, not featured evidence 41.7%Tiered, Weight Based Dosing BIW Then QW NCT01244763 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%2.0 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%1.5 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%1.5 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%1.0 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%1.0 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence 0%0.7 mg/kg BIW NCT00761657 · Phase 2 · registry result, not featured evidence 30.8%0.7 mg/kg TIW NCT00761657 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | — | d constipation 16.9% (placebo 11.1%) hyperkalemia 16% (placebo 12.5%) viral upper respiratory tract infection 15.9% (placebo 13.1%) NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 40 more resultshypertension 28.8% oedema peripheral 14.9% nausea 10.8% NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 hypertension 21.7% (placebo 13.3%) oedema peripheral 11.3% (placebo 10.3%) viral upper respiratory tract infection 9.7% (placebo 4.4%) NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 abdominal infection 7.7% back pain 7.7% hyperkalaemia 7.7% NCT04655027 · Phase 4 · registry result, not featured evidence nasopharyngitis 24.5% diarrhoea 11.9% constipation 9.3% NCT03329196 · Phase 3 · registry result, not featured evidence nasopharyngitis 45.7% diarrhoea 15.4% contusion 13% NCT03439137 · Phase 3 · registry result, not featured evidence catheter site infection 21.4% diarrhoea 19% nasopharyngitis 14.3% NCT03402386 · Phase 3 · registry result, not featured evidence nasopharyngitis 20.8% shunt stenosis 20.8% diarrhoea 16.7% NCT03461146 · Phase 3 · registry result, not featured evidence urinary tract infection 11% (placebo 6.8%) hypertension 10.7% (placebo 8.5%) oedema peripheral 10.4% (placebo 7.7%) NCT02174627 · Phase 3 · registry result, not featured evidence diarrhoea 10.9% hypertension 8.1% headache 7.5% NCT02174731 · Phase 3 · registry result, not featured evidence hypertension 18.4% diarrhea 13.8% muscle spasms 11.5% NCT02052310 · Phase 3 · registry result, not featured evidence nausea 17% vomiting 16.2% hypertension 15.9% NCT02273726 · Phase 3 · registry result, not featured evidence hypertension 15.9% headache 8.7% diarrhoea 8% NCT02278341 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 40% cough 33.3% abdominal pain 20% NCT01630889 · Phase 2 · registry result, not featured evidence 2.0 mg/kg TIW nausea 8.3% (placebo 0%) anaemia 0% (placebo 25%) arteriovenous fistula site complication 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 2.0 mg/kg anaemia 0% (placebo 25%) arteriovenous fistula site complication 0% (placebo 0%) catheter site pain 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 2.0 mg/kg TIW cough 20% (placebo 0%) fatigue 20% (placebo 0%) haemoglobin decreased 20% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 1.8 mg/kg TIW anaemia 16.7% (placebo 25%) diarrhoea 16.7% (placebo 0%) nausea 8.3% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 1.8 mg/kg TIW diarrhoea 16.7% (placebo 0%) anaemia 0% (placebo 25%) arteriovenous fistula site complication 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 1.5 mg/kg TIW diarrhoea 8.3% (placebo 0%) anaemia 0% (placebo 25%) arteriovenous fistula site complication 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 1.5 mg/kg TIW anaemia 25% (placebo 25%) arteriovenous fistula site complication 25% (placebo 0%) catheter site pain 25% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 1.3 mg/kg TIW diarrhoea 16.7% (placebo 0%) anaemia 0% (placebo 25%) arteriovenous fistula site complication 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 1.0 mg/kg TIW nausea 25% (placebo 0%) diarrhoea 8.3% (placebo 0%) anaemia 0% (placebo 25%) NCT01147666 · Phase 2 · registry result, not featured evidence Weight Tiered 70-120-200 mg anaemia 20% (placebo 25%) nausea 10% (placebo 0%) arteriovenous fistula site complication 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence Weight Tiered 70-100-150 mg anaemia 8.3% (placebo 25%) arteriovenous fistula site complication 0% (placebo 0%) catheter site pain 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence Weight Tiered 70-120-200 mg nausea 16.7% (placebo 0%) anaemia 0% (placebo 25%) arteriovenous fistula site complication 0% (placebo 0%) NCT01147666 · Phase 2 · registry result, not featured evidence 100 mg TIW nausea 12.5% diarrhoea 8.3% headache 8.3% NCT01244763 · Phase 2 · registry result, not featured evidence 70 mg BIW Then QW oedema peripheral 16% urinary tract infection 12% nasopharyngitis 8% NCT01244763 · Phase 2 · registry result, not featured evidence 50 mg TIW oedema peripheral 16.7% dizziness 12.5% diarrhoea 8.3% NCT01244763 · Phase 2 · registry result, not featured evidence Tiered, Weight Based Dosing TIW hypertension 16.7% nausea 16.7% diarrhoea 12.5% NCT01244763 · Phase 2 · registry result, not featured evidence Tiered, Weight Based Dosing TIW Then BIW oedema peripheral 20.8% diarrhoea 16.7% urinary tract infection 16.7% NCT01244763 · Phase 2 · registry result, not featured evidence Tiered, Weight Based Dosing BIW Then QW nausea 20.8% urinary tract infection 16.7% constipation 12.5% NCT01244763 · Phase 2 · registry result, not featured evidence 2.0 mg/kg BIW fatigue 18.2% (placebo 0%) back pain 9.1% (placebo 3.6%) diarrhoea 9.1% (placebo 7.1%) NCT00761657 · Phase 2 · registry result, not featured evidence 2.0 mg/kg TIW allergic sinusitis 8.3% (placebo 0%) benign breast neoplasm 8.3% (placebo 0%) cystitis 8.3% (placebo 0%) NCT00761657 · Phase 2 · registry result, not featured evidence 1.5 mg/kg BIW headache 30% (placebo 3.6%) hyperkalaemia 20% (placebo 0%) back pain 10% (placebo 3.6%) NCT00761657 · Phase 2 · registry result, not featured evidence 1.5 mg/kg TIW hyperuricaemia 18.2% (placebo 0%) renal impairment 18.2% (placebo 0%) acidosis 9.1% (placebo 0%) NCT00761657 · Phase 2 · registry result, not featured evidence 1.0 mg/kg BIW diarrhoea 16.7% (placebo 7.1%) anorexia 8.3% (placebo 0%) chills 8.3% (placebo 0%) NCT00761657 · Phase 2 · registry result, not featured evidence 1.0 mg/kg TIW back pain 22.2% (placebo 3.6%) prostatitis 16.7% (placebo 0%) breast cyst 11.1% (placebo 0%) NCT00761657 · Phase 2 · registry result, not featured evidence 0.7 mg/kg BIW anaemia 10% (placebo 0%) hyperkalaemia 10% (placebo 0%) hypernatraemia 10% (placebo 0%) NCT00761657 · Phase 2 · registry result, not featured evidence 0.7 mg/kg TIW diarrhoea 23.1% (placebo 7.1%) abdominal pain 7.7% (placebo 0%) abdominal pain upper 7.7% (placebo 0%) NCT00761657 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dPopulation comparability has not been reviewed for 38 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Roxadustat
show 169 more results
show 5 more results
show 2 more results
show 18 more results
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 2 more results
show 2 more results
+ 61 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Molidustat's landscape · Roxadustat's landscape